Search the Newsreel

Kaplan Fox Announces an Investigation Into Fulcrum Therapeutics

Kaplan Fox & Kilsheimer LLP has initiated an investigation into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) regarding potential securities law violations. This follows a significant drop in Fulcrum's stock price after the company announced the discontinuation of its pociredir program for sickle cell disease due …

Form 4 Fulcrum Therapeutics Inc For: 21 July By Investing.com

This article reports on a Form 4 filing for Fulcrum Therapeutics Inc. dated July 21st, 2026. Form 4 filings typically disclose transactions by company insiders, however, the content beyond the headline is minimal, indicating this islikely an automated news brief. The article notes a …

Fulcrum Therapeutics: director Kevin Tang buys $594k in shares

Kevin Tang, a director and 10% owner of Fulcrum Therapeutics, recently purchased 167,616 shares worth approximately $594,675 over two days in mid-July 2026. This insider buying occurs as FULC stock is significantly down year-to-date and below its 52-week high, following the discontinuation of its …

Fulcrum Therapeutics, Inc. (FULC) insider funds purchase 167,616 shares at ~$3.5

Kevin Tang and affiliated Tang Capital entities, identified as 10% owners of Fulcrum Therapeutics (FULC), indirectly purchased 167,616 shares of common stock on July 16–17, 2026. The shares were acquired at weighted-average prices of $3.56 and $3.52 per share, falling within a trade range …

Fulcrum Therapeutics 10% owner Kevin Tang acquires $594,132 of common shares

Kevin Tang, a 10% owner of Fulcrum Therapeutics through Tang Capital-managed entities, reportedly acquired common shares worth $594,132. The shares were purchased at prices ranging from $3.52 to $3.56, increasing his beneficial ownership to 7,080,945 shares. This information originated from a disclosure filed with …

BlackRock Portfolio Management LLC discloses 6.0% holding in THERAPEUTICS INC (FULC)

BlackRock Portfolio Management LLC has reported a passive ownership stake of 6.0% in THERAPEUTICS INC (FULC), holding 4,021,379 shares as of June 30, 2026. The firm has sole voting power over 3,604,410 shares and sole dispositive power over all 4,021,379 shares, with no individual …

Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm to Learn About Their Legal Rights

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns regarding the drug's benefit-risk profile, leading to a significant …

Form 4 Fulcrum Therapeutics Inc For: 15 July By Investing.com

This article reports on a Form 4 filing for Fulcrum Therapeutics Inc. on July 15. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by …

Fulcrum Therapeutics, Inc. (FULC) gains Tang Capital as 10.4% shareholder

Tang Capital Management, LLC and its affiliated entities have reported a 10.4% beneficial ownership stake in Fulcrum Therapeutics, Inc. (FULC), amounting to 6,913,329 shares. This disclosure, made via an amended Schedule 13G/A filing, indicates shared voting and dispositive power over these shares among the …

Kevin Tang buys $891k of Fulcrum Therapeutics stock

Kevin Tang, a 10% owner of Fulcrum Therapeutics (NASDAQ:FULC) and Tang Capital Management LLC, purchased 249,946 shares of the company's common stock for approximately $891,067 between July 13 and July 15, 2026. These transactions occurred while the stock was near its 52-week low, and …

Fulcrum Therapeutics (FULC) holder adds 249,946 shares in open-market buys

Entities associated with Kevin Tang and Tang Capital Management LLC, a ten percent owner of Fulcrum Therapeutics, Inc. (FULC), purchased 249,946 shares of common stock between July 13 and 15, 2026. The shares were acquired in open-market buys at prices ranging from $3.50 to …

Kaplan Fox & Kilsheimer LLP Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to a Securities Investigation

Kaplan Fox & Kilsheimer LLP has announced a securities investigation into Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a significant drop in its stock price. This investigation comes after Fulcrum Therapeutics discontinued its pociredir program for sickle cell disease due to the FDA's concerns about …

Fulcrum Therapeutics (FULC) insider reports 6,663,383-share Tang Capital stake

What's Driving Fulcrum Lithium's (ASX: FUL) Share Price Lower?

Fulcrum Therapeutics (FULC) director awarded 32,000 options at $3.66

FULC Q1 2026 Earnings: EPS Beat Despite Pre-Revenue Status, Stock Declines - Tech Earnings Analysis

Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring

What's Going On With Fulcrum Therapeutics Stock On Thursday? - Fulcrum Therapeutics (NASDAQ:FULC)

FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud

A Look At Fulcrum Therapeutics (FULC) Valuation After Halting Pociredir And Launching A Broad Review

Why Fulcrum Therapeutics (FULC) Is Down 53.6% After Ending Pociredir And Exploring Strategic Options

Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Lithium (ASX:FUL) Advances Nevada Lithium Project Momentum

Fulcrum Therapeutics (FULC) Hovers Near Support After Marginal Uptick - Covered Call Trade

Why Did Fulcrum Lithium (ASX: FUL) Shares Jump Today?

After Plunging 21.5% in 4 Weeks, Here's Why the Trend Might Reverse for Fulcrum Therapeutics (FULC)

YA II PN emerges with 3.73% stake in Fulcrum Metals

Fulcrum Therapeutics Shares Climb After Q1 Earnings Outperform Expectations

Fulcrum Metals uncovers multi-metal upside in Canadian tailings

FULCRUM THERAPEUTICS ($FULC) Releases Q4 2025 Earnings

Fulcrum Metals (LON:FMET) everything you need to know

What date does Fulcrum Therapeutics's (FULC) report Earnings - Earnings Calendar & Announcement

Fulcrum Therapeutics, Inc. (FULC) stock price, news, quote and history

Fulcrum Therapeutics (FULC) Stock Price, News & Analysis $FULC

Fulcrum Therapeutics (FULC)